Amgen Inc (AMG) Stock Price & News

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics. The company's major products are Prolia and XGEVA to treat osteoporosis and bone diseases, Repatha to treat hyperlipidemia, Otezla to treat psoriasis and psoriatic arthritis, Enbrel to treat autoimmune diseases, Evenity to treat osteoporosis, Tepezza to treat Graves' ophthalmopathy, Blincyto to treat acute lymphoblastic leukemia, Nplate to regulate platelet production, Tezspire to treat asthma, Kyprolis to treat cancer, Aranesp to stimulate erythropoiesis, Krystexxa to treat gout, and Vectibix, a monoclonal antibody. Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection. The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health. Wikipedia

About Amgen Inc

CEOრობერტ ეი ბრედუეი

Employees31,5 ათ.

Founded1980

Headquartersთაუზენდ-ოუკსი, კალიფორნია, ამერიკის შეერთებული შტატები

Sector-

Websiteamgen.com

Revenue

Net income

All values in USD	სექ. 2025	დეკ. 2025	მარ. 2026	ივნ. 2026
Revenue	9,56 მლრდ.	9,87 მლრდ.	8,62 მლრდ.	10,05 მლრდ.
Cost of goods sold	2,74 მლრდ.	2,68 მლრდ.	2,50 მლრდ.	2,75 მლრდ.
Cost of revenue	2,74 მლრდ.	2,68 მლრდ.	2,50 მლრდ.	2,75 მლრდ.
Research and development expenses	1,90 მლრდ.	2,14 მლრდ.	1,72 მლრდ.	1,87 მლრდ.
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	1,72 მლრდ.	1,95 მლრდ.	1,60 მლრდ.	1,74 მლრდ.
Operating expense	3,55 მლრდ.	4,18 მლრდ.	3,21 მლრდ.	3,73 მლრდ.
Total operating expenses	6,29 მლრდ.	6,85 მლრდ.	5,70 მლრდ.	6,48 მლრდ.
Operating income	3,26 მლრდ.	3,01 მლრდ.	2,91 მლრდ.	3,57 მლრდ.
Other non operating income	181,00 მლნ.	143,00 მლნ.	192,00 მლნ.	145,00 მლნ.
EBT including unusual items	3,92 მლრდ.	1,51 მლრდ.	2,08 მლრდ.	2,77 მლრდ.
EBT excluding unusual items	2,72 მლრდ.	2,51 მლრდ.	2,37 მლრდ.	3,06 მლრდ.
Income tax expense	705,00 მლნ.	181,00 მლნ.	265,00 მლნ.	393,00 მლნ.
Effective tax rate	17,98%	11,96%	12,72%	14,20%
Other operating expenses	-71,00 მლნ.	82,00 მლნ.	-113,00 მლნ.	116,00 მლნ.
Net income	3,22 მლრდ.	1,33 მლრდ.	1,82 მლრდ.	2,38 მლრდ.
Net profit margin	33,65%	13,51%	21,11%	23,62%
Earnings per share	5,64	5,29	5,15	6,29
Interest and investment income	-	408,00 მლნ.	-	-
Interest expense	-685,00 მლნ.	-1,06 მლრდ.	-657,00 მლნ.	-673,00 მლნ.
Net interest expenses	-685,00 მლნ.	-653,00 მლნ.	-657,00 მლნ.	-673,00 მლნ.
Depreciation and amortization charges	-	-	-	-
EBITDA	4,57 მლრდ.	4,02 მლრდ.	4,03 მლრდ.	4,69 მლრდ.
Gain or loss from assets sale	-	-	-	-

Ask anything